A staked ETF has finally arrived—but don’t rush to treat it as a price catalyst.

Canary Capital’s staked Injective ETF (INJC) has officially begun trading on Nasdaq. It offers more than just spot exposure to INJ: it also includes on-chain staking rewards in its net asset value, marking a meaningful upgrade to the product structure of spot ETFs.

It’s important to distinguish between two things: the ETF listing provides a subscription channel and adds to the narrative, but whether it can lift INJ’s price in the short term depends on market makers’ pace of building positions and net inflows during the first week. Including staking rewards in NAV makes the product more competitive, but it doesn’t translate into sustained buying pressure on the token itself.

Scenario one to watch: INJC sees strong first-day trading volume and net subscriptions, while spot INJ volume rises in tandem. That would suggest traditional investors are seriously building exposure to INJ. Scenario two: the ETF attracts only token allocations while spot volume fails to pick up—in that case, the price will likely spike and then pull back.

Are you watching first-day net subscriptions more closely, or changes in spot INJ trading volume?

Source: The Block

Image 1: Canary’s staked INJ ETF lists on Nasdaq · Key news points
Image source: https://www.theblock.co/news/markets/2026-11-05-canary-staked-inj-etf-launches-nasdaq-injc-435115